62 reports of this reaction
1.9% of all ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE reports
#12 most reported adverse reaction
INSOMNIA is the #12 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, manufactured by The Procter & Gamble Manufacturing Company. There are 62 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE to INSOMNIA. This represents approximately 1.9% of all 3,300 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 62 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 1.9% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, making it a notable side effect.
If you experience insomnia while taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.